Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction.
Ajani
Jaffer A
JA
Department of Gastrointestinal Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA. jajani@mdanderson.org
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001661:Biliary Tract Neoplasms / Q000188:drug therapy*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D004943:Esophagogastric Junction; D006801:Humans; D000077146:Irinotecan
D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin